For most AML patients, continuous activation of the PI3K/AKT/mTOR signaling pathway results in a constitutive phosphorylation and activation of AKT at Ser473 by mTORC2 [38,39]. The gene discussed is MTOR; the disease is acute myeloid leukemia.